Supplementary Video 1 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

Supplementary Video 1 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis

<p>Supplementary Video 1</p>

Na minha lista:

Detalhes bibliográficos
Autor principal:	Debarati Mukherjee (15134436) (author)
Outros Autores:	Rebecca A. Previs (16918344) (author), Corinne Haines (16918347) (author), Muthana Al Abo (16918350) (author), Patrick K. Juras (15134430) (author), Kyle C. Strickland (16918353) (author), Binita Chakraborty (16918356) (author), Sandeep Artham (15086158) (author), Regina S. Whitaker (16918359) (author), Katherine Hebert (16918362) (author), Jake Fontenot (16918365) (author), Steven R. Patierno (16918368) (author), Jennifer A. Freedman (16918371) (author), Frank H. Lau (16918374) (author), Matthew E. Burow (16918377) (author), Ching-Yi Chang (15134445) (author), Donald P. McDonnell (15051446) (author)
Publicado em:	2025
Assuntos:	Cancer Tumor Biology Molecular and Cellular Biology Therapeutic Research and Development Breast Cancer Cell Signaling Protein serine-threonine kinases Drug Targets Protein kinase & phosphatase drug targets Progression, Invasion & Metastasis Metastasis Migration and invasion
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados

Supplementary Video 2 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
Por: Debarati Mukherjee (15134436)
Publicado em: (2025)

Supplementary Video 3 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
Por: Debarati Mukherjee (15134436)
Publicado em: (2025)

Supplementary Video 4 from Targeting CaMKK2 Inhibits Actin Cytoskeletal Assembly to Suppress Cancer Metastasis
Por: Debarati Mukherjee (15134436)
Publicado em: (2025)

Supplementary Movie S1 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Por: Jesse C. Patterson (14962862)
Publicado em: (2025)

Supplementary Movie S2 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Por: Jesse C. Patterson (14962862)
Publicado em: (2025)

Supplementary Movie S3 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Por: Jesse C. Patterson (14962862)
Publicado em: (2025)

Supplementary Movie S4 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Por: Jesse C. Patterson (14962862)
Publicado em: (2025)

Supplementary Movie S5 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Por: Jesse C. Patterson (14962862)
Publicado em: (2025)

Supplementary Movie S6 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Por: Jesse C. Patterson (14962862)
Publicado em: (2025)

Supplementary Movie S7 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Por: Jesse C. Patterson (14962862)
Publicado em: (2025)

Supplementary Movie S8 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Por: Jesse C. Patterson (14962862)
Publicado em: (2025)

Supplementary Movie S9 from Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling
Por: Jesse C. Patterson (14962862)
Publicado em: (2025)

Supplementary Table S1 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Por: Clare F. Malone (14960925)
Publicado em: (2025)

Supplementary Table S2 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Por: Clare F. Malone (14960925)
Publicado em: (2025)

Supplementary Table S3 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Por: Clare F. Malone (14960925)
Publicado em: (2025)

Supplemental Data File S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Por: Katie E. Hebron (15046889)
Publicado em: (2025)

Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Por: Katie E. Hebron (15046889)
Publicado em: (2025)

Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Por: Katie E. Hebron (15046889)
Publicado em: (2025)

Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Por: Katie E. Hebron (15046889)
Publicado em: (2025)

Supplementary Data File S7 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Por: Katie E. Hebron (15046889)
Publicado em: (2025)

Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Por: Katie E. Hebron (15046889)
Publicado em: (2025)

Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
Por: Katie E. Hebron (15046889)
Publicado em: (2025)

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Por: Evan C. Chen (15054014)
Publicado em: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Por: Evan C. Chen (15054014)
Publicado em: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Por: Evan C. Chen (15054014)
Publicado em: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Por: Evan C. Chen (15054014)
Publicado em: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Por: Evan C. Chen (15054014)
Publicado em: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Por: Evan C. Chen (15054014)
Publicado em: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Por: Srivandana Akshintala (16610490)
Publicado em: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
Por: Srivandana Akshintala (16610490)
Publicado em: (2025)

Supplementary Figure 1 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Por: Anne-Florence Blandin (15056366)
Publicado em: (2025)

Supplementary Figure 2 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Por: Anne-Florence Blandin (15056366)
Publicado em: (2025)

Supplementary Figure 3 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Por: Anne-Florence Blandin (15056366)
Publicado em: (2025)

Supplementary Figure 4 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Por: Anne-Florence Blandin (15056366)
Publicado em: (2025)

Supplementary Figure 5 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Por: Anne-Florence Blandin (15056366)
Publicado em: (2025)

Supplementary Figure 6 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Por: Anne-Florence Blandin (15056366)
Publicado em: (2025)

Supplementary Tables 1-8 from <i>ALK</i> Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma
Por: Anne-Florence Blandin (15056366)
Publicado em: (2025)

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Por: Erwin Tomasich (15052256)
Publicado em: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Por: Erwin Tomasich (15052256)
Publicado em: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
Por: Erwin Tomasich (15052256)
Publicado em: (2025)

Cannot write session to /tmp/vufind_sessions/sess_lcmv564kqrh40609qmogncov62